We develop medicines to defeat diseases of aging

Andreas Christensen is Co-founder and Chief Executive Officer of Roxiant. He leads our management team, business strategy, fund raising, and strategic partnerships.

Before Roxiant, Andreas served in a variety of strategic and operational leadership roles over a 10-year career at Pharmacosmos. Most recently, he headed up its operations in the UK & Ireland, where he led a tripling of annual revenues to £10 million, an organisational expansion from 15 to 50 people, and forged multiple research partnerships.

Andreas has a MSc in Engineering from the Technical University of Denmark and an MBA from the European School of Management & Technology in Berlin.

Nationality: Danish

Kasper is Co-founder and Chief Operating Officer of Roxiant. He leads our business planning and operations, scientific development, and patent portfolio strategy.

Kasper has a strong hybrid specialization in molecular science, intellectual property and life science business planning. Prior to co-founding Roxiant, Kasper was Chief Executive Officer and Co-founder of a vaccine platform technology company, which he led from the discovery to preclinical stage, whilst raising more than EUR 1.5 million in soft funding, and successfully optimising the company’s patent portfolio.

Kasper holds a BSc in Molecular Biology from Aarhus University and a MSc in BioBusiness from the Copenhagen Business School.

Nationality: Danish

Bob Clay is Chief Regulatory Officer of Roxiant. He leads our regulatory affairs strategy and operations and quality management.

He has more than 30 years’ experience in drug development, leading the global regulatory approval of many products across a range of therapy areas including metabolic diseases, neuroscience, cancer, and infection, involving more than 15 new substances.

Bob has served as Vice President of Global Regulatory Affairs for oncology, infection, and personalised healthcare at AstraZeneca, as Global Regulatory Therapeutic Area Head for Neurosciences at Pfizer, and as Chief Regulatory Officer at Kinapse.

He holds a BPharm in Pharmacy from University of Bath, a MSc in BioPharmacy from King’s College, and an MBA from The Open University in England.

Nationality: British

Søren Salling is Chief Medical Officer of Roxiant. He leads our medical strategy and operations and clinical partnerships.

Before Roxiant, Søren held various international medical leadership roles at international pharma companies, including MSD and Pharmacosmos, where he was responsible for developing and implementing medical strategies, particularly for pre-launch phase and specialist products.

Søren holds a degree of Medical Doctor from the University of Southern Denmark and an MBA from Maastricht University.

Nationality: Danish

Kishor Modha is CMC Projects Director of Roxiant. He leads our CMC strategy, project management and supplier engagement.

He has more than 20 years of CMC strategy and operations expertise within the biotech industry developing biologics, gene and cell therapy products. He has extensive experience in directing and managing biotherapeutic development programs from early pre-clinical stage through IND/IMPD enabling studies and into clinical development.

Kishor has a BSc in Microbiology and a PhD in Biotechnology from University of Surrey in England.

Nationality: British

Jay Modha is CMC Technical Director of Roxiant. He is our technical CMC lead and responsible for GMP manufacturing process design, product specifications and analytical methods.

Jay has more than 20 years of senior CMC expertise in GMP process development and production of conventional biologics and autologous or allogeneic cell and gene therapy medicinal products and recombinant viral vaccines in accordance with EU/US directives and ICH, EMA, FDA guidelines for clinical (Phase I, II or III) and commercial manufacture.

Jay has a BSc in Microbiology from University of Surrey and a PhD in Parasite Immunology from London School of Hygiene and Tropical Medicine in England.

Nationality: British

Rasmus Just is Co-founder and Chairman of Roxiant.

Rasmus currently serves as Global Head Business Development at ALK, the global specialty pharma company pioneering allergy immunotherapy. Before that, Rasmus served various strategic and operational leadership positions in R&D and business development over a 12-year career at Zealand Pharma, a research-led Danish specialty pharma company.

At Zealand Pharma, Rasmus established a long-term strategic partnership with Boehringer Ingelheim. He has served on the board of directors of several life science and medtech companies, including Zealand Pharma.

Rasmus has a PhD in Molecular Pharmacology from Copenhagen University and an MBA from AVT Business School in Denmark.

Nationality: Danish

Prof Annibale Alessandro Puca is Scientific Founder, Board Member and Scientific Chair of Roxiant.

Prof Puca is a Medical Doctor and Full Professor at the University of Salerno in Italy. He has published more than 130 peer reviewed scientific papers and is the co-inventor of several patents and patent applications.

Prof Puca is a scientific expert on genetics of aging and exceptional longevity and the leading expert on the longevity-associated LAV-BPIFB4. LAV-BPIFB4 research has been the centerpiece of this academic work since 2010.

Earlier in his career, he has worked as an Instructor at Harvard Medical School and in 2001 he co-founded Centagenetix Inc., a genomics-based drug discovery company in the U.S., where he worked as Vice President of Research until 2003.  

Nationality: Italian

Prof Ferdinando Nicoletti is Co-founder, Board Member and Clinical Chair of Roxiant.

Prof Nicoletti is a Medical Doctor and Full Professor of General Pathology and Immunology at University of Catania in Italy. He is recognised as one of the Top Italian Scientists for his in vitro and in vivo research in immunoinflammatory and auto-immune diseases and cancer.

Prof Nicoletti has published more than 330 peer reviewed scientific papers and is the co-inventor of 5 patents and patent applications.

Prior to co-founding Roxiant, Prof Nicoletti was co-founder and Chief Scientific Officer in three biotech companies in Denmark, Norway and the U.S. with successful exits.

Nationality: Italian

Assistant Professor Niels Henning Skotte is the Chair of Roxiant's Scientific Advisory Board. He advises on Huntington's Disease, translational research, and biomarkers for clinical trials.

Dr. Skotte is a neuroscientist and clinical mass spectrometry specialist at the the Novo Nordisk Foundation Center for Protein Research (NNF CPR) at the University of Copenhagen with an expertise in personalized gene therapy, proteomics, biomarker discovery, and neurodegeneration.

He was awarded an esteemed three-year post-doctoral fellowship from Canadian Institutes of Health Research (CIHR) while working at the Centre for Molecular Medicine and Therapeutics, Vancouver (CMMT), Canada, with the world-leading expert in Huntington's Disease, Professor Michael Hayden. Subsequently, he specialized in clinical proteomics in Professor Matthias Mann’s laboratory, who is an elite researcher and pioneer in modern protein research.

Dr. Skotte has been working on Huntington's Disease for more than 10 years with 28 peer-reviewed scientific papers. He is a dedicated lecturer in gene therapy, the central nervous system, and pharmacology. Dr. Skotte is working on identifying novel biomarkers and therapeutic targets for neurodegenerative diseases using cerebrospinal fluid and plasma. He is committed to finding a treatment for patients suffering from Huntington's Disease.

Nationality: Danish

Prof Alberto Auricchio is Scientific Advisor to Roxiant. He advises on gene therapy and adeno-associated viral vector drug delivery.

Prof Auricchio is a Medical Doctor, Professor of Medical Genetics at Naples Medical School and Director of Molecular Therapy Program at TIGEM (Telethon Institute of Genetics and Medicine) in Italy. He is the author of 15 international patents and more than 130 peer-reviewed scientific papers. He has been the principal investor of more than 25 studies.  

Prof Auricchio is a member of the Editorial boards of Human Gene Therapy and Molecular Therapy. He received the 2006 Outstanding New Investigator Award of the American Society of Gene Therapy and was nominated in 2007 as "Cavaliere of the Italian Republic" by the President of the Italian Republic.

Nationality: Italian

Dr. Elena Ciaglia is Scientific Advisor to Roxiant. She advises on translational research and mechanistic study design.

Dr. Ciaglia is an immunologist and Research Fellow at the University of Salerno in Italy with expertise in translational medicine. She is a leading preclinical researcher of LAV-BPIFB4. She is the author of multiple peer-reviewed scientific papers and co-inventor of one international patent.

During her PhD in Oncology and Molecular Endocrinology, Dr. Ciaglia worked for some time at the Laboratory of Immunoregulation at the US National Institute of Allergy and Infectious Diseases. Later, Dr. Ciaglia was awarded a prestigious three-year fellowship from Fondazione Italiana Ricerca sul Cancro (FIRC) and a three-years post doc fellowship from Fondazione Umberto Veronesi in translational immunology.

Nationality: Italian

Klaus Berding is Corporate Advisor to Roxiant. He advises our management and board of directors on financing strategies and investor relations.

Klaus has extensive experience from a 30-year senior executive career in corporate finance, capital markets, research and business development within biotech and technology. He has been involved in more than 50 public and private equity funding projects surpassing a transaction volume of EUR 1 billion.

After a successful career as Senior Vice President in the Healthcare team of Dresdner Kleinwort Wasserstein, he set up his own consultancy and became Director and Associated Partner of Breslin, a life science corporate finance operation and former Biotech venture fund. Klaus has start-up experience from co-founding Amypopharma Srl, a spin-off from University of Milano-Bicocca in Italy. He also actively participates in the TechTour as an expert and coach for more than 10 years.

Klaus has a Master in Economics & Business Administration with a focus on Banking, Corporate Finance and International Economics.

Nationality: German

Alexander Peitersen is Corporate Advisor to Roxiant. He advises our management and board of directors on corporate strategy and investor relations.

Currently, Alexander services as corporate strategic advisor to multiple life science companies and executives. For more than 17 years, Alexander was co-founder and CEO of the Nordic healthcare agency REPUTATION, a global lead agency for life science companies such as Lundbeck, UCB and Genmab. After selling to Publicis Groupe, he continued as regional CEO for the conglomerate.

Alexander has a MSc in Biochemistry (Oncology) from Copenhagen University and an MBA from Copenhagen Business School.

Nationality: Danish